These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 26178435)

  • 1. Cardiovascular pharmacogenomics: current status and future directions.
    Roden DM
    J Hum Genet; 2016 Jan; 61(1):79-85. PubMed ID: 26178435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenomics and cardiovascular disease.
    Weeke P; Roden DM
    Curr Cardiol Rep; 2013 Jul; 15(7):376. PubMed ID: 23689943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is personalized medicine a dream or a reality?
    Morse BL; Kim RB
    Crit Rev Clin Lab Sci; 2015 Feb; 52(1):1-11. PubMed ID: 25181036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PHARMACOGENOMIC DETERMINANTS OF RESPONSE TO CARDIOVASCULAR DRUGS.
    Stankov KM; Stanimirov BG; Mikov MM
    Med Pregl; 2015; 68(7-8):259-65. PubMed ID: 26591639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenomic Challenges in Cardiovascular Diseases: Examples of Drugs and Considerations for Future Integration in Clinical Practice.
    Chatelin J; Stathopoulou MG; Arguinano AA; Xie T; Visvikis-Siest S
    Curr Pharm Biotechnol; 2017; 18(3):231-241. PubMed ID: 28117005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aspirin, warfarin and a thienopyridine for acute coronary syndromes.
    Konstantino Y; Iakobishvili Z; Porter A; Sandach A; Zahger D; Hod H; Hammerman H; Gottlieb S; Behar S; Hasdai D
    Cardiology; 2006; 105(2):80-5. PubMed ID: 16286733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetics in cardiovascular disorders: an update on the principal drugs.
    Predazzi IM; Mango R; Norata GD; Di Daniele N; Sergi D; Romeo F; Novelli G
    Am J Cardiovasc Drugs; 2013 Apr; 13(2):79-85. PubMed ID: 23539170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent developments and future directions for the use of pharmacogenomics in cardiovascular disease treatments.
    Berinstein E; Levy A
    Expert Opin Drug Metab Toxicol; 2017 Sep; 13(9):973-983. PubMed ID: 28792790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular pharmacogenetics: a promise for genomically-guided therapy and personalized medicine.
    Zaiou M; El Amri H
    Clin Genet; 2017 Mar; 91(3):355-370. PubMed ID: 27714756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetics, pharmacogenomics, and cardiovascular therapeutics: the way forward.
    Terra SG; Johnson JA
    Am J Cardiovasc Drugs; 2002; 2(5):287-96. PubMed ID: 14727958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opportunities and Challenges in Cardiovascular Pharmacogenomics: From Discovery to Implementation.
    Roden DM; Van Driest SL; Wells QS; Mosley JD; Denny JC; Peterson JF
    Circ Res; 2018 Apr; 122(9):1176-1190. PubMed ID: 29700066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-drug interactions between clopidogrel and novel cardiovascular drugs.
    Pelliccia F; Rollini F; Marazzi G; Greco C; Gaudio C; Angiolillo DJ
    Eur J Pharmacol; 2015 Oct; 765():332-6. PubMed ID: 26341013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenomics of lipid-lowering therapies.
    Hu M; Tomlinson B
    Pharmacogenomics; 2013 Jun; 14(8):981-95. PubMed ID: 23746191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular pharmacogenomics: the future of cardiovascular therapeutics?
    Roden DM
    Can J Cardiol; 2013 Jan; 29(1):58-66. PubMed ID: 23200096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid-lowering drugs.
    Med Lett Drugs Ther; 2016 Oct; 58(1506):133-140. PubMed ID: 27755510
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacogenomics of cardiovascular drugs and adverse effects in pediatrics.
    Visscher H; Amstutz U; Sistonen J; Ross CJ; Hayden MR; Carleton BC
    J Cardiovasc Pharmacol; 2011 Sep; 58(3):228-39. PubMed ID: 21386709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetics testing: implications for cardiovascular therapeutics with clopidogrel and warfarin.
    George J; Doney A; Palmer CN; Lang CC
    Cardiovasc Ther; 2010 Jun; 28(3):135-8. PubMed ID: 20557312
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacogenetics of antiplatelets and anticoagulants: a report on clopidogrel, warfarin and dabigatran.
    Ross S; Paré G
    Pharmacogenomics; 2013 Oct; 14(13):1565-72. PubMed ID: 24088127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prognostic model based on readily available clinical data enriched a pre-emptive pharmacogenetic testing program.
    Schildcrout JS; Shi Y; Danciu I; Bowton E; Field JR; Pulley JM; Basford MA; Gregg W; Cowan JD; Harrell FE; Roden DM; Peterson JF; Denny JC
    J Clin Epidemiol; 2016 Apr; 72():107-15. PubMed ID: 26628336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenetics in Cardiovascular Medicine.
    Weeke PE
    Adv Pharmacol; 2018; 83():333-360. PubMed ID: 29801582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.